AN INTEGRATED PHASE 2/3 AND PHASE 3 TRIAL OF MRD-BASED OPTIMIZATION OF ADJUVANT THERAPY IN UROTHELIAL CAN (MODERN)
Principal Investigator: Dr. Eric Knoche
Co-Investigators: Dr. Erik Shannon and Jason Atkinson
Muscle-invasive urothelial cancer of the bladder is associated with a high risk of metastatic recurrence despite curative intent surgery. The purpose of this study is to see if adjuvant PD-1 blockade with nivolumab improves disease-free survival in patients with muscle-invasive urothelial cancer at high risk for recurrence.
This project is in the final process of approval and will be open to enrollment soon.
To learn more about MODERN and how you can join contact our research office at (314) 289-7690
This project is a joint study with the St. Louis VA and The Washington University in St. Louis.
This study is funded by the Foundation through the NCI (National Center Institute)
Co-Investigators: Dr. Erik Shannon and Jason Atkinson
Muscle-invasive urothelial cancer of the bladder is associated with a high risk of metastatic recurrence despite curative intent surgery. The purpose of this study is to see if adjuvant PD-1 blockade with nivolumab improves disease-free survival in patients with muscle-invasive urothelial cancer at high risk for recurrence.
This project is in the final process of approval and will be open to enrollment soon.
To learn more about MODERN and how you can join contact our research office at (314) 289-7690
This project is a joint study with the St. Louis VA and The Washington University in St. Louis.
This study is funded by the Foundation through the NCI (National Center Institute)